Search PubMed⌕ Search

Biomedical subjects

M Wheatley

Publications and source records attributed to M Wheatley.

At least 37 records · Page 2Linked to original sources
PubMed1999

Nurses on board.

Explore the source record for details and available documents.

Decision Making, Organizational↗
PubMed1998

Localisation of arginine vasopressin V1a receptors on sympatho-adrenal preganglionic neurones.

Vasopressin-containing nerve terminals are present in the spinal cord of several species. This study was designed to determine whether sympatho-adrenal preganglionic neurones (SPN) express vasopressin receptors (VPRs). SPN in the spinal cord were revealed by retrograde labelling of Fluorogold following its unilateral injection into the adrenal medulla of 12-20 day postnatal rats. VPRs were simultaneously visualised in the Fluorogold-labelled slices of spinal cord using a recently developed biotinylated vasopressin receptor antagonist [1-phenylacetyl,2-O-methyl-D-tyrosine,6-arginine,8-arginine,9-lysinam ide(Nepsilon-biotinamidocaproamide)]vasopressin, PhAcAL(Btn)VP. The VPR:PhAcAL(Btn)VP complexes were visualised either with Texas Red-conjugated avidin or with a Vectastain avidin:alkaline phosphatase detection kit. These dual-labelling experiments revealed VPRs to be present in the spinal grey matter and to be particularly dense in the intermediate grey matter and adjacent regions of the ventral horn. Many SPN were associated with receptor-specific labelling of PhAcAL(Btn)VP, thereby demonstrating that VPRs are expressed by these neurones. These VPRs were pharmacologically defined as the V1a subtype. It is concluded that sympatho-adrenal preganglionic neurones express VPRs and that these are of the V1a subtype. The distribution of VPRs is not, however, restricted to these SPN in the spinal cord.

Adrenal Glands↗
PubMed1998

Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormone-mastoparan constructs.

Ca2+ efflux, Ca(2+)-ATPase, and membrane permeability measurements were used to investigate the biochemical mechanisms of Ca2+ release induced by mastoparan (MP) and the chimeric hormone-MP constructs incorporating galanin (galparan) or vasopressin antagonist (M375 and M391) moieties. Comparative studies utilised preparations of porcine cerebellar microsomes and rabbit skeletal muscle sarcoplasmic reticulum (SR). MP and chimeric peptides galparan, M375 and M391 induce Ca2+ release over a range of concentrations from 0.3-10 microM. Comparison of MP and three chimeric, N-terminal extended, constructs indicates that N-terminal extension modifies the biological properties of MP, producing changes in efficacy which are enzyme-isoform-specific. Biochemical studies indicate that the chimeric analogues and MP inhibit Ca(2+)-ATPases and directly activate the ryanodine receptor (RyR) to release Ca2+ from both heavy SR (HSR) and microsomes. The same peptides have no effect on the InsP3 receptor (InsP3R). Other actions that include modest changes in membrane permeability may also contribute to the Ca(2+)-mobilising action of MP and chimeric constructs.

Amino Acid Sequence↗
PubMed1998

Understanding neurotransmitter receptors: molecular biology-based strategies.

Neurotransmitter receptor proteins can be divided into GPCRs and ligand-gated ion channels. Members within each family utilize a similar signalling mechanism and are structurally related. Multiple receptor subtypes are expressed for individual neurotransmitters, generating orders of complexity that have been exploited for therapeutic intervention. GPCRs have been cloned and extensively studied by using a range of molecular biological strategies, particularly recombinant expression systems. These have located functional domains for ligand binding and G-protein coupling. A combination of molecular biology and computer modelling has increased our understanding of receptor activation and will aid drug design.

Animals↗
PubMed1998

Characterization of G protein-coupled receptors expressed by ECV304 human endothelial cells.

The aims of this study were to characterize G protein-coupled receptors endogenously expressed by ECV304 human endothelial cells, and to determine the utility of this transformed cell line as a vehicle for the expression of cloned receptors. Cellular responses to a broad range of agonists were determined by measuring changes in the intracellular content of second messengers (inositol phosphates and cyclic adenosine monophosphate). These studies identified H1 histamine receptors, P2U-purinoceptors and lysophosphatidic acid receptors which are functionally coupled to phosphoinositidase C. G protein-coupled receptors which bind adenosine (A2 receptor), calcitonin, and adrenaline (beta-adrenoceptor), and markedly stimulate adenylyl cyclase, are also endogenously expressed by ECV304. Agonists which did not stimulate ECV304 cells are: angiotensin II, angiotensin1-7, bombesin, bradykinin, desArg9-bradykinin, carbachol, endothelin-1, neurotensin, serotonin, substance K, substance P, thrombin and vasopressin. The rat Via vasopressin receptor was expressed by lipofection in two antibiotic-resistant clonal lines and expression confirmed by measuring agonist-induced changes in inostol phosphate production. We conclude that the ECV304 cell line is a suitable in vitro system to study the signal transduction pathways of some endogenous G protein-coupled receptors known to modulate endothelial function in vivo. ECV304 is also appropriate for the expression and functional characterization of cloned receptor proteins.

Animals↗
PubMed1997

Chimeric strategies for the rational design of bioactive analogs of small peptide hormones.

The aim of this study was to evaluate a variety of synthetic strategies pertinent to the development of chimeric analogs of the structurally divergent nonapeptide hormones arginine vasopressin (AVP) and bradykinin (BK). Single-chain peptides combining AVP and BK directly, AVP(1-9)-BK(1-9) or via a flexible aminohexanoic acid (epsilonAhx) linker, AVP(1-9)-epsilonAhx-BK(1-9), bind with relatively high affinity to the bovine kidney medulla B2a bradykinin receptor (B2a BKR). Significantly, amino-terminal extended chimeric analogs of BK, including AVP(1-9)-BK(1-9) and galanin(1-13)-BK(1-9), are functional B2 BKR agonists. These findings illustrate that chimeric peptides can activate G-protein-coupled receptors (GPCRs) in a manner analogous to that of endogenous monomeric agonists. Further development, combining the sequences of receptor subtype-selective antagonists, produced high-affinity chimeric antagonists of the V1a vasopressin receptor (V1a VPR) and the B2a BKR. We also determined the pharmacological characteristics of high-affinity chimeric hormone analogs derivatized with the membrane targeting function of mastoparan. Homodimers of an amino-terminal extended BK analog and a V1a-selective antagonist represent the first examples of new classes of B2 BKR and V1a VPR antagonists, respectively. These findings are discussed in relation to the GPCR binding site for small peptides and the development of novel biological probes and therapeutic agents.

Amino Acid Sequence↗